Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Operating Expenses (2018 - 2025)

Historic Other Operating Expenses for Agios Pharmaceuticals (AGIO) over the last 8 years, with Q2 2025 value amounting to $1.7 million.

  • Agios Pharmaceuticals' Other Operating Expenses rose 1384.62% to $1.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 9862.11%. This contributed to the annual value of $200.0 million for FY2024, which is N/A changed from last year.
  • Per Agios Pharmaceuticals' latest filing, its Other Operating Expenses stood at $1.7 million for Q2 2025, which was up 1384.62% from $1.1 million recorded in Q1 2025.
  • Agios Pharmaceuticals' Other Operating Expenses' 5-year high stood at $200.0 million during Q3 2024, with a 5-year trough of -$9.9 million in Q4 2022.
  • In the last 5 years, Agios Pharmaceuticals' Other Operating Expenses had a median value of $1.9 million in 2021 and averaged $15.2 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Other Operating Expenses surged by 24295.77% in 2021 and then crashed by 47514.21% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Other Operating Expenses (Quarter) stood at $2.6 million in 2021, then tumbled by 475.14% to -$9.9 million in 2022, then surged by 111.19% to $1.1 million in 2023, then soared by 17950.54% to $200.0 million in 2024, then tumbled by 99.15% to $1.7 million in 2025.
  • Its Other Operating Expenses stands at $1.7 million for Q2 2025, versus $1.1 million for Q1 2025 and $200.0 million for Q3 2024.